Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 31 July 2013 | By Alexander Gaffney, RAC,
Newly revised user fees are set to come into effect next week in the EU for certain pharmacovigilance reporting forms, the European Medicines Agency (EMA) has announced, providing a substantial benefit to members of industry.
The user fees relate to Type IA variation forms used to immediately report major pharmacovigilance events, including:
The good news for sponsors, however, is that EMA has decided to fully waive the entire fee for all of the aforementioned Type IA variation form submissions. Such exemptions will reportedly apply whether or not the notifications were done individually, grouped, or combined into another application.
Revised EMA Guidance on User Fees (Page 35/36)
Regulatory Focus newsletters
All the biggest regulatory news and happenings.